TRI Monthly SEMINAR SERIES

Date & Time

“With dynamic, changing exhibition programs, MOD. inspires young adults aged 15+ about science and technology, showcasing how research shapes our understanding of the world to inform the future.”

“With dynamic, changing exhibition programs, MOD. inspires young adults aged 15+ about science and technology, showcasing how research shapes our understanding of the world to inform the future.”

Date & Time

Dr Herb Kressel, Harvard

Professor Felipe Prosper MD,PhD

Head of the Hematology and Cell Therapy Department

University of Navarra, Spain

Title: "Harnessing Epigenetics to improve diagnoses and treatment of cancer."

Professor Prosper graduated from the University of Navarra in 1989 and after his residency and PhD he completed his fellowship and postdoctoral training at the University of Minnesota. Relocated to the Clinica Universidad de Navarra in 2001, he was responsible for the development of the cell therapy program where he became the Head of Hematology and Cell Therapy in 2003 and Director of the programs of Hematology and Cell Therapy at the center for Applied Medical Research at the University of Navarra in 2012.

Prosper has published more than 280 peer review articles in top journals including New England Journal of Medicine, Nature Genetics or Blood among others, with an h-factor of 53 and over 9890 citations.

Tuesday 20 March 

12.00 - 1.00pm 

Dr Cameron Turtle 

Fred Hutch Cancer Centre Seattle, Clinical Trials Immunotherapy 

Dr Kristen Radford, Mater

Dr. Turtle is currently an Attending Physician on the Fred Hutch Bone Marrow Transplant Program and the Immunotherapy Service at the Seattle Cancer Care Alliance (SCCA), a cancer treatment center that unites doctors from Fred Hutch, University of Washington Medicine and Seattle Children’s Hospital.

Dr Cameron Turtle Full Biography 

Dr Boris Holzapfel

Dr. med. at Ludwigs-Maximilians University of Munich, Bavaria, Germany

Title: 'Patient Specific Design, Planning and Surgery of Complex Orthopaedic Tumor Cases'

Dr Boris Holzapfel is an orthopaedic oncologist and surgeon with outstanding experience in the treatment of primary and secondary tumours of the musculoskeletal system. In this context he is trying to implement bone tissue engineering approaches into surgical therapy concepts of these tumours.

His translational research is focused on the biology of bone and soft tissue sarcomas and on the molecular mechanisms that lead to the development of bone metastases. By combining his knowledge about bone tissue engineering and tumour biology, he established several novel xenograft models of bone metastasis that make it possible to analyse the species-specific mechanisms of human cancer cell osteotropism.

Date & Time

30 May 2017 *Please note date change

12.00 - 1.00pm 

Prof Alan Mackay-Sim, 2017 Australian of the Year

Dr Alexandre Cristino

Hereditary Spastic Paraplegia: from stem cells to drug discovery

6 June 2017

12.00 - 1.00pm 

A/Prof Michael Samuel, Head Tumour Microenvironment Lab, Centre for Cancer Biology,

SA Pathology & the University of South Australia

Prof Rik Thompson

Biochemical and biomechanical inter-relationships in cancer and wound healing

Title: Rewriting the transcriptome: ADAR1 mediated A-to-I RNA editing

One of the most prevalent forms of post-transcriptional RNA modification is the conversion of adenosine bases to inosine (A-to-I), mediated by the ADAR family of enzymes. A-to-I editing is a widespread feature of the transcriptome, with estimates ranging from tens of thousands in mice to millions of A-to-I editing events in humans and primates. We have used in vivo haematology as a system to understand how RNA editing by ADAR1 regulates the transcriptome, and how this interfaces with the innate immune system and enables discrimination of self and non-self nucleic acids.​

Imagine 2017